Understanding and preventing risks of opioid use during pregnancy
Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy
This study is looking to help pregnant women with Opioid Use Disorder and their babies by creating a tool that predicts who might face challenges during and after pregnancy, so they can get better support and care.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Opalgenix, INC. NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10683849 on NIH RePORTER |
What this research studies
This research focuses on predicting and preventing adverse outcomes for mothers and their children affected by Opioid Use Disorder (OUD) during pregnancy. It aims to develop a risk prediction tool that identifies pregnant women at high risk for relapse and their newborns at risk for Neonatal Opioid Withdrawal Syndrome (NOWS). The study will analyze genetic factors and other variables to create a comprehensive approach to improve treatment and outcomes. By addressing the mental health aspects, such as anxiety and depression, the research seeks to enhance the overall care for these vulnerable populations.
Who could benefit from this research
Good fit: Ideal candidates for this research include pregnant women with Opioid Use Disorder and their newborns.
Not a fit: Patients who are not pregnant or do not have Opioid Use Disorder may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prediction and prevention strategies for mothers with OUD, ultimately improving health outcomes for both mothers and their children.
How similar studies have performed: Previous research has shown that genetic factors can influence treatment outcomes in opioid use, suggesting potential for success in this novel approach.
Where this research is happening
Indianapolis, United States
- Opalgenix, INC. — Indianapolis, United States (Active)
Researchers
- Principal investigator: Plump, Steven R. — Opalgenix, INC.
- Study coordinator: Plump, Steven R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.